Sugi Predict

Sugi Predict / Compounds / SCHEMBL856267

SCHEMBL856267

SCHEMBL856267

COC(=O)C1CC(C)CC1=O

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TLR4 O00206 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ BRD4 O60885 1/20 0.38
▸ MMP2 P08253 1/20 0.34
▸ ANPEP P15144 1/20 0.34
▸ CHRNB2 P17787 2/20 0.33
▸ CHRNA4 P43681 2/20 0.33
▸ CHRNB4 P30926 1/20 0.33
▸ CHRNA3 P32297 1/20 0.33
▸ CHRNA7 P36544 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ KMT2A Q03164 2/20 0.32
▸ ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3643881 1.00 TLR4 (0.39) TLR4ALDH1A1BRD4MMP2ANPEP
SCHEMBL13036801 1.00 TLR4 (0.39) TLR4ALDH1A1BRD4MMP2ANPEP
SCHEMBL6923072 0.82 ALDH1A1 (0.38) TLR4ALDH1A1BRD4MMP2ANPEP
SCHEMBL4548466 0.82 ALDH1A1 (0.38) TLR4ALDH1A1BRD4MMP2ANPEP
SCHEMBL11013935 0.81 MAPK1 (0.42) TLR4ALDH1A1
SCHEMBL11013938 0.81 MAPK1 (0.42) TLR4ALDH1A1
SCHEMBL2784766 0.81 BRD4 (0.44) ALDH1A1BRD4MMP2ANPEPCHRNB2
SCHEMBL7715093 0.80 BRD4 (0.46) ALDH1A1BRD4MMP2ANPEPCHRNB2
SCHEMBL11676672 0.79 ALDH1A1 (0.49) TLR4ALDH1A1KMT2A
SCHEMBL27868499 0.79 BRD4 (0.42) ALDH1A1BRD4MMP2ANPEPCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
EP-4681774-A2 KHK INHIBITORS Gilead Sciences, Inc. (US) 2026-01-21 — — EP disclosed
EP-4313967-B1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2025-11-12 — — EP disclosed
US-12410160-B2 KHK inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
EP-4063358-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2024-05-22 — — EP disclosed
EP-4313967-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-07 — — EP disclosed
CN-117120429-A KHK inhibitor 吉利德科学公司 2023-11-24 — — CN disclosed
US-11713299-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-08-01 — — US disclosed
US-20230079863-A1 KHK INHIBITORS GILEAD SCIENCES, INC. 2023-03-16 — — US disclosed
WO-2022212194-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2022-10-06 — — WO disclosed
US-20090298925-A1 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS DURST GREGORY LEE 2009-12-03 — — US disclosed
US-7585985-B2 Substituted benzopyrans as selective estrogen receptor-beta agonists ELI LILLY AND COMPANY (US) 2009-09-08 — — US disclosed
US-20080312312-A1 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS DURST GREGORY LEE 2008-12-18 — — US disclosed
US-7442812-B2 Substituted benzopyrans as selective estrogen receptor-beta agonists ELI LILLY AND COMPANY (US) 2008-10-28 — — US disclosed
EP-1626974-B1 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS LILLY CO ELI (US) 2008-08-27 — — EP disclosed
CN-100374444-C Substituted benzopyran compounds as selective beta-estrogen receptor agonists YILE LILY CO LTD (US) 2008-03-12 — — CN disclosed
US-20070106082-A1 Substituted benzopyrans as selective estrogen receptor-beta agonists ELI LILLY AND COMPANY 2007-05-10 — — US disclosed
CN-1777614-A Substituted benzopyran compounds as selective beta-estrogen receptor agonists LILLY CO ELI (US) 2006-05-24 — — CN disclosed
EP-1626974-A2 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2006-02-22 — — EP disclosed
WO-2004094400-A2 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2004-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070106082-A1 Substituted benzopyrans as selective estrogen receptor-beta agonists MCHR1, MCHR2, MC1R TLR4 2322/4885ALDH1A1 788/4885BRD4 1458/4885
US-20090298925-A1 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS GPER1, ESR2, ESR1 TLR4 659/4885ALDH1A1 847/4885BRD4 611/4885
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 TLR4 1232/4885ALDH1A1 700/4885BRD4 3107/4885
US-20230079863-A1 KHK INHIBITORS KHK, KHDRBS1, NADK TLR4 4824/4885ALDH1A1 1520/4885BRD4 952/4885
US-12410160-B2 KHK inhibitors KHK, KHDRBS1, NADK TLR4 4824/4885ALDH1A1 1520/4885BRD4 952/4885
US-20080312312-A1 SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS GPER1, ESR2, ESR1 TLR4 659/4885ALDH1A1 847/4885BRD4 611/4885
US-11713299-B2 Histone methyltransferase inhibitors EHMT1, DOT1L, EHMT2 TLR4 4594/4885ALDH1A1 420/4885BRD4 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.